Sheerin Shahidi-Latham

Sheerin Shahidi-Latham has a vast and diverse work experience in the field of pharmaceuticals and biotechnology. Starting in 2002, Sheerin worked at Procter & Gamble as a Researcher in the Fabric and Home Care Division. This involved evaluating the effectiveness of enzyme additives in Tide detergent and contributing to the development of a microscale assay.

In 2007, Sheerin joined Genentech as an Associate Scientist in the Imaging MS Group of the Drug Metabolism & Pharmacokinetics (DMPK) department. Over the years, Sheerin took on roles of increasing responsibility within Genentech, including Scientist, Metabolomics & Imaging MS Group Leader, and eventually Senior Scientist, Metabolomics & Imaging MS Group Leader.

During this time, Sheerin led a team of 8 members in support of imaging MS, metabonomics/biomarker discovery, and lead compound generation/optimization. Sheerin also served as the DMPK Team Leader for small molecule oncology discovery project teams, responsible for coordinating, managing, and reporting in vitro ADME and in vivo PK, PK/PD, and TK studies. Sheerin's contributions included PK modeling, human PK predictions, and dose projections, resulting in the nomination of two compounds for clinical development.

Sheerin's work at Genentech also involved leading the DMPK Team for a development program, overseeing IND-enabling in vitro ADME and in vivo PK, PK/PD, and TK studies. Sheerin played a role in the IND filing submitted in March 2013.

In 2018, Sheerin moved to MyoKardia, where they held various positions, including Staff Scientist, Head of Discovery DMPK, and R&D Biomarker Team Leader. Sheerin also served as a Director in Drug Metabolism & Pharmacokinetics, overseeing the area of biomarkers, and later as Senior Director, Biomarkers.

Most recently, Sheerin joined Bristol Myers Squibb in 2020 as Senior Director in the ICF Translational Development Disease Team of the Translational Medicine department. Here, Sheerin played a key role in the field of translational medicine and contributed to the development of disease-specific strategies.

In 2021, Sheerin transitioned to Nitrase Therapeutics, taking on the role of Vice President, Preclinical Development.

Throughout their career, Sheerin Shahidi-Latham has demonstrated expertise in preclinical development, biomarkers, drug metabolism and pharmacokinetics, and imaging MS. Sheerin has a proven track record of leadership and successful contributions to clinical development programs.

Sheerin Shahidi-Latham completed their Bachelor of Science degree with a major in Biochemistry and a minor in French at Miami University from 1998 to 2001. Following this, they pursued further education and obtained a Doctor of Philosophy (Ph.D.) degree in Chemistry/Biochemistry from Vanderbilt University, which they completed from 2002 to 2007. In terms of additional certifications, Sheerin Shahidi-Latham received training in Pharmacokinetics for Pharmaceutical Scientists at UCSF in 2008, although the specific month of obtaining the certification is unknown.